1. Home
  2. SOPH vs LUNG Comparison

SOPH vs LUNG Comparison

Compare SOPH & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOPHiA GENETICS SA

SOPH

SOPHiA GENETICS SA

HOLD

Current Price

$4.61

Market Cap

330.4M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$2.53

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOPH
LUNG
Founded
2011
1995
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
330.4M
63.6M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
SOPH
LUNG
Price
$4.61
$2.53
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$7.00
$6.81
AVG Volume (30 Days)
100.5K
1.1M
Earning Date
11-04-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$73,297,000.00
$91,664,000.00
Revenue This Year
$18.32
$9.21
Revenue Next Year
$15.61
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
13.66
15.59
52 Week Low
$2.58
$1.31
52 Week High
$5.30
$9.37

Technical Indicators

Market Signals
Indicator
SOPH
LUNG
Relative Strength Index (RSI) 49.82 70.76
Support Level $4.54 $1.96
Resistance Level $4.84 $1.74
Average True Range (ATR) 0.30 0.20
MACD -0.03 0.10
Stochastic Oscillator 29.03 88.74

Price Performance

Historical Comparison
SOPH
LUNG

About SOPH SOPHiA GENETICS SA

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: